Lukas Scheibler's most recent trade in Apellis Pharmaceuticals Inc was a trade of 10,000 Common Stock done at an average price of $60 . Disclosure was reported to the exchange on Dec. 1, 2023.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Apellis Pharmaceuticals Inc | Lukas Scheibler | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 01 Dec 2023 | 10,000 | 68,299 (0%) | 0% | 60 | 600,000 | Common Stock |
Apellis Pharmaceuticals Inc | Scheibler Lukas | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.85 per share. | 01 Dec 2023 | 10,000 | 78,299 (0%) | 0% | 13.9 | 138,500 | Common Stock |
Apellis Pharmaceuticals Inc | Scheibler Lukas | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2023 | 10,000 | 39,391 | - | - | Stock Option (Right to Buy) | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | Chief Research Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 14,023 | 14,023 | - | - | Stock Option (Right to Buy) | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | Chief Research Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 9,886 | 70,358 (0%) | 0% | 0 | Common Stock | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | Chief Research Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.50 per share. | 21 Feb 2023 | 715 | 69,643 (0%) | 0% | 58.5 | 41,828 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | Chief Research Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.21 per share. | 10 Feb 2023 | 678 | 60,472 (0%) | 0% | 51.2 | 34,720 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | Chief Research Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.77 per share. | 27 Jan 2023 | 542 | 61,150 (0%) | 0% | 52.8 | 28,601 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | Chief Research Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.05 per share. | 20 Jan 2023 | 2,015 | 61,692 (0%) | 0% | 52.1 | 104,881 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | Chief Research Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 35,472 | 35,472 | - | - | Stock Option (Right to Buy) | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | Chief Research Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 22,580 | 63,707 (0%) | 0% | 0 | Common Stock | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Other type of transaction at price $ 0.00 per share. | 21 Apr 2022 | 11,250 | 0 | - | - | Stock Option (Right to Buy) | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Sale of securities on an exchange or to another person at price $ 43.00 per share. | 21 Apr 2022 | 10,000 | 40,358 (0%) | 0% | 43 | 430,000 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Other type of transaction at price $ 0.00 per share. | 21 Apr 2022 | 1,875 | 50,358 (0%) | 0% | 0 | Common Stock | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Sale of securities on an exchange or to another person at price $ 60.09 per share. | 05 Apr 2022 | 609 | 52,233 (0%) | 0% | 60.1 | 36,593 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2022 | 609 | 49,391 | - | - | Stock Option (Right to Buy) | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.85 per share. | 05 Apr 2022 | 609 | 52,842 (0%) | 0% | 13.9 | 8,435 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2022 | 3,504 | 50,000 | - | - | Stock Option (Right to Buy) | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.85 per share. | 04 Apr 2022 | 3,504 | 55,737 (0%) | 0% | 13.8 | 48,530 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Sale of securities on an exchange or to another person at price $ 56.86 per share. | 04 Apr 2022 | 1,437 | 53,482 (0%) | 0% | 56.9 | 81,714 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Sale of securities on an exchange or to another person at price $ 57.80 per share. | 04 Apr 2022 | 1,249 | 52,233 (0%) | 0% | 57.8 | 72,198 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Sale of securities on an exchange or to another person at price $ 55.84 per share. | 04 Apr 2022 | 818 | 54,919 (0%) | 0% | 55.8 | 45,677 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.85 per share. | 01 Apr 2022 | 11,496 | 63,729 (0%) | 0% | 13.9 | 159,220 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 11,496 | 53,504 | - | - | Stock Option (Right to Buy) | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Sale of securities on an exchange or to another person at price $ 55.05 per share. | 01 Apr 2022 | 11,496 | 52,233 (0%) | 0% | 55.1 | 632,855 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.73 per share. | 14 Feb 2022 | 720 | 52,233 (0%) | 0% | 26.7 | 19,246 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 720 | 133,777 | - | - | Stock Option (Right to Buy) | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Sale of securities on an exchange or to another person at price $ 46.80 per share. | 11 Feb 2022 | 1,666 | 51,513 (0%) | 0% | 46.8 | 77,969 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.85 per share. | 10 Feb 2022 | 10,000 | 63,179 (0%) | 0% | 13.9 | 138,500 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 10 Feb 2022 | 10,000 | 53,179 (0%) | 0% | 50 | 500,000 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 10,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.12 per share. | 10 Feb 2022 | 678 | 53,179 (0%) | 0% | 47.1 | 31,947 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2022 | 10,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.85 per share. | 08 Feb 2022 | 10,000 | 63,857 (0%) | 0% | 13.9 | 138,500 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 08 Feb 2022 | 10,000 | 53,857 (0%) | 0% | 45 | 450,000 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Sale of securities on an exchange or to another person at price $ 38.47 per share. | 28 Jan 2022 | 1,233 | 53,857 (0%) | 0% | 38.5 | 47,434 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.59 per share. | 28 Jan 2022 | 642 | 55,090 (0%) | 0% | 38.6 | 24,775 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 36,951 | 36,951 | - | - | Stock Option (Right to Buy) | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 26,051 | 55,732 (0%) | 0% | 0 | Common Stock | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.73 per share. | 21 Jan 2022 | 3,021 | 29,681 (0%) | 0% | 26.7 | 80,751 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2022 | 3,021 | 134,497 | - | - | Stock Option (Right to Buy) | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 10 Jun 2021 | 3,417 | 26,651 (0%) | 0% | 60 | 205,020 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.72 per share. | 10 Feb 2021 | 680 | 29,290 (0%) | 0% | 47.7 | 32,450 | Common Stock |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 11,250 | 11,250 | - | - | Stock Option (Right to Buy) | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 7,500 | 28,095 (0%) | 0% | 0 | Common Stock | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 1,875 | 29,970 (0%) | 0% | 0 | Common Stock | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2020 | 7,482 | 137,518 | - | - | Stock Option (Right to Buy) | |
Apellis Pharmaceuticals Inc | Lukas Scheibler | CHIEF INNOVATION OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.73 per share. | 08 Dec 2020 | 7,482 | 20,595 (0%) | 0% | 26.7 | 199,994 | Common Stock |